Key Drivers
- Strong liquidity
- Heavy cash burn
- Rich valuation
AIAI Summary
ALMS has shifted from a speculative psoriasis story to a near-term FDA execution trade, with strong ONWARD3 efficacy and a $503.7m cash cushion supporting the NDA path, but investors now need clearer safety/commercial proof and better operating execution to justify the rich valuation and weak technical trend.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Heavy cash burn
- •Rich valuation
ALMS has a strong liquidity and leverage cushion, but persistent losses, heavy cash burn, and extremely rich sales multiples make the stock fundamentally dependent on balance-sheet strength rather than earnings power.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Near-term support
- •Overhead resistance
Over the last month, ALMS remains in a bearish-to-neutral downtrend, with $24.40 acting as near-term support but strong resistance overhead near $27.10-$27.80 until that zone is reclaimed.
Repeated rebounds stalled below prior highs, signaling persistent overhead supply
Sentiment & News
Key News Insights:
- •Skin clearance
- •ONWARD3 momentum
- •Institutional buying
Alumis is building strong clinical momentum for envudeucitinib in psoriasis, with standout skin-clearance data and growing institutional interest reinforcing a positive outlook for ALMS.
The latest clinical and ownership updates are likely supportive for ALMS, as they strengthen confidence in envudeucitinib's commercial potential and treatment differentiation
Similar Companies in Healthcare
Other companies in the same sector with AI ratings